Literature DB >> 24331196

Symptom management and psychosocial outcomes following cancer.

Charles W Given1, Barbara A Given2.   

Abstract

Transition from the completion of cancer treatment to post-treatment is a pivotal first step in survivorship. Following the end of treatment patients may experience lingering symptoms, compromised physical function, and emotional distress. Within the larger survivorship literature less attention has been devoted to this immediate post acute treatment period. To organize this review a post-treatment risk model is presented; it is informed by the emotional health and comorbid conditions patients bring to their treatment. When integrated with the aggressiveness of treatment(s), the side effects experienced, and emotional responses, this profile defines and characterizes patients' post-treatment needs. Some patients need little more than a standard survivorship care plan with clearly defined shared care responsibilities for the oncologist and primary care physician. Others need more and varied forms of assistance. This review documents the range of physical and psychosocial problems patients' face as they transition from active treatment to survivorship. We conclude with suggestions for future research tailored to patient's post-treatment needs for care.
© 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 24331196     DOI: 10.1053/j.seminoncol.2013.09.001

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  7 in total

1.  Using SMART design to improve symptom management among cancer patients: A study protocol.

Authors:  Alla Sikorskii; Gwen Wyatt; Rebecca Lehto; David Victorson; Terry Badger; Thaddeus Pace
Journal:  Res Nurs Health       Date:  2017-11-11       Impact factor: 2.228

2.  Reasons for not reaching or using web-based self-management applications, and the use and evaluation of Oncokompas among cancer survivors, in the context of a randomised controlled trial.

Authors:  A van der Hout; C F van Uden-Kraan; K Holtmaat; F Jansen; B I Lissenberg-Witte; G A P Nieuwenhuijzen; J A Hardillo; R J Baatenburg de Jong; N L Tiren-Verbeet; D W Sommeijer; K de Heer; C G Schaar; R J E Sedee; K Bosscha; M W M van den Brekel; J F Petersen; M Westerman; J Honings; R P Takes; I Houtenbos; W T van den Broek; R de Bree; P Jansen; S E J Eerenstein; C R Leemans; J M Zijlstra; P Cuijpers; L V van de Poll-Franse; I M Verdonck-de Leeuw
Journal:  Internet Interv       Date:  2021-07-15

Review 3.  Mechanisms, Predictors, and Challenges in Assessing and Managing Painful Chemotherapy-Induced Peripheral Neuropathy.

Authors:  Grace A Kanzawa-Lee; Robert Knoerl; Clare Donohoe; Celia M Bridges; Ellen M Lavoie Smith
Journal:  Semin Oncol Nurs       Date:  2019-04-30       Impact factor: 2.315

4.  Emotional Problems, Quality of Life, and Symptom Burden in Patients With Lung Cancer.

Authors:  Eleshia J Morrison; Paul J Novotny; Jeff A Sloan; Ping Yang; Christi A Patten; Kathryn J Ruddy; Matthew M Clark
Journal:  Clin Lung Cancer       Date:  2017-03-02       Impact factor: 4.840

Review 5.  Cancer survivors' experiences of using survivorship care plans: a systematic review of qualitative studies.

Authors:  Sharon Keesing; Beverley McNamara; Lorna Rosenwax
Journal:  J Cancer Surviv       Date:  2014-10-25       Impact factor: 4.442

6.  Use and Appreciation of a Tailored Self-Management eHealth Intervention for Early Cancer Survivors: Process Evaluation of a Randomized Controlled Trial.

Authors:  Iris Maria Kanera; Roy A Willems; Catherine A W Bolman; Ilse Mesters; Victor Zambon; Brigitte Cm Gijsen; Lilian Lechner
Journal:  J Med Internet Res       Date:  2016-08-23       Impact factor: 5.428

7.  Long-term effects of a web-based cancer aftercare intervention on moderate physical activity and vegetable consumption among early cancer survivors: a randomized controlled trial.

Authors:  Iris M Kanera; Roy A Willems; Catherine A W Bolman; Ilse Mesters; Peter Verboon; Lilian Lechner
Journal:  Int J Behav Nutr Phys Act       Date:  2017-02-10       Impact factor: 6.457

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.